David Parkinson, MD

Interim Chief Executive Officer

Previously President & CEO of ESSA Pharma (Nasdaq: EPIX), where he led the company through Phase 2 clinical development and raised ~$150M. Prior roles include VP of Global Clinical Development at Novartis and Venture Partner at NEA. Brings over 30 years of experience advancing therapeutics from clinical stage to public markets.